Blood filter device tested to fight COVID-19 organ failure

NCT ID NCT04547257

Ongoing Disease control Sponsor: ExThera Medical Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests a device called Seraph 100, a blood filter used to treat severe COVID-19. The goal is to see if filtering the blood can reduce organ failure in patients with COVID-19 who are in the intensive care unit. The study enrolled 42 adults with confirmed COVID-19 and organ problems. Researchers measure changes in organ function over 48 hours and track survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Seraph 100 blood filter
What this could lead to: If it works, this could provide a new way to treat severe COVID-19 by filtering harmful substances from the blood, potentially reducing organ failure and improving survival.
What could go wrong: This is a small early study with only 42 participants, so results may not apply to everyone. The device is experimental and may not improve outcomes or could cause complications from the filtering process.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Hospital Clinico San Carlos

Madrid, 28040, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Klinikum Aschaffenburg-Alzenau

Aschaffenburg, 63739, Germany
Universitätsklinikum Essen

Essen, 45147, Germany
Vivantes Klinikum Neukölln

Berlin, 12351, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.